Clinical Research

We’ve performed research across the country where we’ve gained valuable knowledge. We continue to grow by expanding our research studies.

Hover over a dot to see the clinical research being conducted at each location

United States

Group 4

Arizona

California

Florida

Kansas

Minnesota

New York

North Carolina

Ohio

Texas

Canada

Group 10

Ontario

Research Centers (All)(USA)(canada)

Arizona

Mayo Clinic

Jeanne Palmer, MD

California

Cedars-Sinai Medical Center

Ronald Paquette, MD

Florida

Moffitt Cancer Center

Rami Komrokji, MD

Kansas

University of Kansas Medical Center

Abdulraheem Yacoub, MD

Minnesota

University of Michigan Rogel Cancer Center

Moshe Talpaz, MD

New York

Icahn School of Medicine at Mount Sinai

John Mascarenhas (PI), MD

Memorial Sloan Kettering Cancer Center

Raajit Rampal, MD, PhD

North Carolina

Wake Forest University Health Sciences

Rupali Bhave, MD

Ohio

Cleveland Clinic

Aaron Gerds, MD

Ontario

University Health Network

Vikas Gupta, MD

Texas

UT Health San Antonio

Ruben Mesa (co-PI), MD

Clinical Research

Active Trials

Upcoming Trials

Closed Trials

MPN-RC 106

MPN-RC 106 Research Tissue Bank

Study Status

This study is Active.

Myeloproliferative Neoplasms Research Consortium, July 2019

MPN-RC 106 Summary

The MPN-RC Research Tissue Bank plans to collect and store tissue specimens from patients with MPNs including (polycythemia vera [PV], essential thrombocythemia [ET], primary myelofibrosis [PMF]) and pre-fibrotic myelofibrosis [Pre-PMF]). Pre-PMF is a recently appreciated early indolent form of myelofibrosis (MF) which can progress to more overt forms of MF as well as to acute leukemia.   These tissue samples will be used to conduct laboratory investigations within the laboratory-based scientific projects of the MPN-RC to help define mechanisms involved in the pathophysiology, progression and effects of treatment of myelofibrosis. We anticipate enrolling 375 subjects to this study and will perform serial yearly tissue banking from each enrolled subject over a 5 year period.

Patients with the myeloproliferative neoplasms (MPNs) polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) suffer progressive cytopenias, bone marrow fibrosis and/or transformation to acute leukemia. These neoplasms are relatively rare, and therefore individual investigators at a single institution cannot obtain tissues from sufficiently large numbers of patients to reach statistically valid conclusions within a reasonable time frame.  This study is aimed to credential novel therapeutic approaches which can then be transitioned to the clinic for near-term mechanism based clinical trials in this research consortium. There is a need for new treatments for myelofibrosis (MF) patients based on laboratory insight into disease pathogenesis. We will use primary patient samples to understand how different genetic mutations contribute to MF development and to test novel treatment approaches.

Eligibility Criteria:

Inclusion Criteria:

  • Newly diagnosed patients diagnosed with Philadelphia chromosome negative myeloproliferative neoplasms (MPN) polycythemia vera (PV), prefibrotic myelofibrosis (Pre-PMF), overt primary myelofibrosis (PMF), essential thrombocythemia (ET), and myeloproliferative neoplasm blast phase (MPN-blast phase) as well as patients previously treated for an MPN.
  • Signed informed consent is required from each patient at the time of enrollment.

Exclusion Criteria:

  • Patients currently participating in experimental treatment arms of MPN-RC protocols, or other experimental treatment protocols.